UBS Group’s Protara Therapeutics TARA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.31M | Buy |
1,402,413
+186,876
| +15% | +$1.11M | ﹤0.01% | 3670 |
|
|
2025
Q4 | $6.48M | Buy |
1,215,537
+372,463
| +44% | +$2.07M | ﹤0.01% | 3758 |
|
|
2025
Q3 | $3.67M | Sell |
843,074
-292,693
| -26% | -$948K | ﹤0.01% | 4355 |
|
|
2025
Q2 | $3.44M | Buy |
1,135,767
+499,093
| +78% | +$1.72M | ﹤0.01% | 4257 |
|
|
2025
Q1 | $2.71M | Buy |
636,674
+487,266
| +326% | +$2.18M | ﹤0.01% | 4419 |
|
|
2024
Q4 | $789K | Buy |
149,408
+141,990
| +1,914% | +$459K | ﹤0.01% | 5489 |
|
|
2024
Q3 | $13.6K | Buy |
+7,418
| New | +$15.2K | ﹤0.01% | 7580 |
|
|
2024
Q2 | – | Sell |
-3,725
| Closed | -$14.9K | – | 10076 |
|
|
2024
Q1 | $14.9K | Buy |
3,725
+2,809
| +307% | +$9.06K | ﹤0.01% | 7050 |
|
|
2023
Q4 | $1.72K | Buy |
916
+795
| +657% | +$1.17K | ﹤0.01% | 8239 |
|
|
2023
Q3 | $202 | Buy |
+121
| New | +$277 | ﹤0.01% | 8709 |
|
|
2023
Q2 | – | Sell |
-971
| Closed | -$3.04K | – | 9635 |
|
|
2023
Q1 | $3.04K | Sell |
971
-1,329
| -58% | -$4.39K | ﹤0.01% | 8393 |
|
|
2022
Q4 | $6.16K | Buy |
2,300
+2,061
| +862% | +$6.5K | ﹤0.01% | 9073 |
|
|
2022
Q3 | $1K | Sell |
239
-1,032
| -81% | -$3.5K | ﹤0.01% | 10037 |
|
|
2022
Q2 | $4K | Buy |
1,271
+697
| +121% | +$2.55K | ﹤0.01% | 9127 |
|
|
2022
Q1 | $3K | Buy |
+574
| New | +$3.02K | ﹤0.01% | 9485 |
|
|
2021
Q3 | – | Sell |
-99
| Closed | -$1K | – | 10072 |
|
|
2021
Q2 | $1K | Sell |
99
-1,338
| -93% | -$15.2K | ﹤0.01% | 9191 |
|
|
2021
Q1 | $23K | Buy |
1,437
+776
| +117% | +$14.4K | ﹤0.01% | 7247 |
|
|
2020
Q4 | $16K | Buy |
661
+523
| +379% | +$11.3K | ﹤0.01% | 7118 |
|
|
2020
Q3 | $2K | Sell |
138
-532
| -79% | -$12.3K | ﹤0.01% | 7691 |
|
|
2020
Q2 | $20K | Buy |
670
+298
| +80% | +$9.22K | ﹤0.01% | 6564 |
|
|
2020
Q1 | $9K | Buy |
372
+170
| +84% | +$4.95K | ﹤0.01% | 7015 |
|
|
2019
Q4 | $132K | Sell |
202
-598
| -75% | -$6.86K | ﹤0.01% | 5860 |
|
|
2019
Q3 | $8K | Buy |
+800
| New | +$11.5K | ﹤0.01% | 7294 |
|
|
2019
Q1 | – | Sell |
-30
| Closed | -$3K | – | 8154 |
|
|
2018
Q4 | $3K | Buy |
+30
| New | +$2.12K | ﹤0.01% | 7734 |
|
|
2018
Q3 | – | Sell |
-55
| Closed | -$5K | – | 8257 |
|
|
2018
Q2 | $5K | Buy |
55
+52
| +1,733% | +$4.85K | ﹤0.01% | 7479 |
|
|
2018
Q1 | $0 | Sell |
3
-145
| -98% | -$13.2K | ﹤0.01% | 8151 |
|
|
2017
Q4 | $11K | Buy |
148
+145
| +4,833% | +$11.6K | ﹤0.01% | 6969 |
|
|
2017
Q3 | $0 | Hold |
3
| – | – | ﹤0.01% | 7986 |
|
|
2017
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 7972 |
|
|
2017
Q1 | $0 | Sell |
3
-67
| -96% | -$5.01K | ﹤0.01% | 7957 |
|
|
2016
Q4 | $5K | Buy |
70
+62
| +775% | +$19.6K | ﹤0.01% | 7255 |
|
|
2016
Q3 | $3K | Buy |
+8
| New | +$2.81K | ﹤0.01% | 7303 |
|
|
2016
Q1 | – | Sell |
-28
| Closed | -$17K | – | 8155 |
|
|
2015
Q4 | $17K | Buy |
28
+21
| +300% | +$12.3K | ﹤0.01% | 6911 |
|
|
2015
Q3 | $4K | Sell |
7
-7
| -50% | -$4.33K | ﹤0.01% | 7842 |
|
|
2015
Q2 | $10K | Buy |
+14
| New | +$8.66K | ﹤0.01% | 7475 |
|
|
2015
Q1 | – | Sell |
-28
| Closed | -$12K | – | 9355 |
|
|
2014
Q4 | $12K | Buy |
+28
| New | +$11.3K | ﹤0.01% | 8241 |
|
Other funds holding TARA
VCIM
VCM
SCM
ACA
IHAM
ACM
UBS Group's TARA Position: Q1 2026 in Review
UBS Group increased its Protara Therapeutics (TARA) stake by 15% in Q1 2026, buying an estimated $1.11M and bringing the position to 1,402,413 shares worth $7.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3670.
UBS Group first reported a position in TARA in Q4 2014 and has held it in 36 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.
- UBS Group held 1,402,413 shares of Protara Therapeutics worth $7.31M as of Q1 2026.
- UBS Group bought 186,876 Protara Therapeutics shares in Q1 2026, an estimated $1.11M.
- Protara Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3670 holding.
- UBS Group first reported a position in Protara Therapeutics in Q4 2014 and has held it in 36 quarters since.
- 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.